Plexus Partners

Bora Pharmaceuticals completes acquisition of US Sterile Fill/Finish Facility From Emergent! Bora is expanding its expertise in biologics with the addition of a new facility located in Baltimore-Camden, Maryland. This site introduces drug product fill/finish capabilities to Bora's already extensive range of services. The facility spans 87,000 square feet and specializes in manufacturing sterile injectable products. It provides non-viral aseptic fill/finish for vials and pre-filled syringes, supporting both clinical trials and commercial production. The facility also offers lyophilization, formulation development, and other key support services across four filling lines. According to Bobby Sheng, CEO and Chairman of Bora Group, the acquisition of this Camden facility marks another significant step forward. "Following our recent acquisition of Upsher-Smith Laboratories, this addition enhances our footprint in North America, strengthens our capabilities for biologics clients, and pushes us closer to becoming a fully integrated global CDMO. We’re excited about the opportunities this site brings and look forward to working with the highly talented team in Camden," Sheng said. https://buff.ly/4dB2hLQ

Jupiter Endovascular emerges with $21m for endoportal pivotal trial

Amid sales slump, Avantor sells off its clinical services business for $650m

Sanyou Bio Launches AI-Powered Antibody Design Platform

Lilly Completes $3.2B Acquisition of Morphic

Emmes, Miimansa AI Partner on Generative AI in Clinical Research Emmes Group, a specialty tech-enabled global CRO, entered a multi-year strategic partnership with Miimansa AI aimed at advancing clinical research at Emmes, leveraging Miimansa’s Clinical Entity Modeling tools based on advanced large language modeling (LLM) techniques and generative AI.

ViroCell Biologics Completes Oversubscribed Convertible Note Offering. ViroCell Biologics, a cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) specializing in GMP viral vector manufacturing for clinical trials, has completed an oversubscribed convertible note offering led by new investor First Light Asset Management LLC plus existing investors including Sartorius Stedim Biotech S.A. and Dorset Opportunity Fund LP.

3 Key Trends Shaping the CDMO Industry in 2024 and Beyond. #cdmo #contractmanufacturing #pharmaceuticals

Haemonetics to buy Attune Medical for $160M. Attune’s device to help cool the esophagus during radiofrequency ablation procedures is a key piece of the acquisition. #Haemonetics #Ablation #RFAblation.

Shape Memory Medical Inc. has secured $38 million in financing to propel the development of custom shape memory polymers for endovascular embolization, a promising field in minimally invasive medical procedures. This funding marks a significant milestone for the company, allowing it to advance its innovative technology aimed at improving patient outcomes and revolutionizing endovascular treatments. With this substantial financial backing, Shape Memory Medical is poised to make strides in the medical industry, showcasing its commitment to pioneering solutions in vascular care. #vascular #peripheralvascular #neurovascular